In this article, we will list the 5 Most Oversold Healthcare Stocks to Invest In. Please visit 8 Most Oversold Healthcare Stocks to Invest In if you would like to see the extended list and the methodology behind it.
5. Viridian Therapeutics, Inc. (NASDAQ:VRDN)
Viridian Therapeutics, Inc. (NASDAQ:VRDN) is one of the most oversold healthcare stocks to invest in. Truist cut the price target on Viridian Therapeutics, Inc. (NASDAQ:VRDN) to $36 from $40 on April 8 but maintained a Buy rating on the shares. The rating update came as part of a broader research note previewing fiscal Q1 earnings in Biotech, with the firm telling investors in the research note that reactivity to regulatory and policy shifts across the sector is continuing to ease. Truist also stated that it is seeing a recent pickup in deal activity, which holds the potential to build momentum through the remainder of the year into midterms.
For Viridian Therapeutics, Inc. (NASDAQ:VRDN), Truist noted that although it has slightly tempered its ultimate expectations on the company’s commercial opportunity in TED, with Veli’ peaking at $630 million in 2031 and Ele’ peaking at $1.14 billion in 2035, the debate is likely to continue as investors and even docs balance the real-world utility of Viridian Therapeutics, Inc.’s (NASDAQ:VRDN) reduced therapeutic burden value prop with Amgen’s existing doc, patient, and payer relationships and existing commercial infrastructure and support.
Viridian Therapeutics, Inc. (NASDAQ:VRDN) is a biopharmaceutical company involved in the development of medicines for autoimmune and rare diseases. The company employs antibody discovery and protein engineering for the creation of new therapies, and is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) while also developing a potential TSHR-targeted treatment for TED and Graves’ disease.
4. Insulet Corporation (NASDAQ:PODD)
Insulet Corporation (NASDAQ:PODD) is one of the most oversold healthcare stocks to invest in. Insulet Corporation (NASDAQ:PODD) received a rating update from Truist on April 15. The firm cut the price target on the stock to $315 from $360 and reaffirmed a Buy rating on the shares. The rating update came as part of a broader research note previewing fiscal Q1 results in the MedTech sector.
Truist told investors in the research note that the firm anticipates fiscal Q1 performances to be in line or better than what feels like an anxious investor sentiment around the fiscal Q1 volumes. It further stated that while the stock trades at a slight discount compared to its peer group average of high-growth profitable companies, Truist believes that it should trade at in-line levels, if not at a premium, to its peer group, given its higher revenue and profit growth prospects.
Insulet Corporation (NASDAQ:PODD) also received a rating update from RBC Capital on April 14, with the firm cutting the price target on the stock to $325 from $380 while reiterating an Outperform rating on the shares.
Insulet Corporation (NASDAQ:PODD) is a medical device company that develops, markets, and manufactures an insulin infusion system for people with insulin-dependent diabetes. The company specializes in diabetes supplies, along with other diabetes related products and supplies, including pump supplies, traditional insulin pumps, blood glucose testing supplies, and pharmaceuticals.
3. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the most oversold healthcare stocks to invest in. Truist cut the price target on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) to $505 from $515 on April 13, reiterating a Buy rating on the shares. The rating update came as part of a broader research note previewing Q1 results among Biotech names. The firm told investors in a research note that although management was confident in robust year-over-year growth, it cautioned for fiscal Q1 seasonal weakness in the United States from typical payer dynamics and 2 fewer shipping weeks.
In a separate development, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) announced on March 24 a set of strategic efforts aimed at accelerating earlier recognition and improving care coordination for patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). The company is advancing, through complementary initiatives with Viz.ai and the American Heart Association, a comprehensive, system‑level approach addressing the continuous challenges of underdiagnosis and fragmented care in ATTR‑CM.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is a biopharmaceutical company that develops and commercializes novel therapeutics based on ribonucleic acid interference.
2. Veeva Systems Inc. (NYSE:VEEV)
Veeva Systems Inc. (NYSE:VEEV) is one of the most oversold healthcare stocks to invest in. Veeva Systems Inc. (NYSE:VEEV) was downgraded to Neutral from Buy by Citi on April 10, with the firm bringing the price target on the stock down to $176 from $291. The firm told investors in a research note that it is “turning more selective” in the application software group with six downgrades, and added that the rating changes highlight its view of underweight software. Citi sees a lack of catalysts for the stocks over the next 12 months.
In a separate development, Veeva Systems Inc. (NYSE:VEEV) announced the acquisition of Ostro on March 10, which is a brand engagement platform for life sciences that gives patients and doctors immediate, compliant answers through an easy-to-use AI-driven chat experience.
Management stated that Veeva Systems Inc. (NYSE:VEEV) acquired Ostro for a purchase price of around $100 million in cash and long-term equity retention grants, and added that Ostro will continue its operations as an independent unit led by CEO Chase Feiger.
Veeva Systems Inc. (NYSE:VEEV) provides industry cloud solutions for the global life science industry. Its offerings include cloud software, data, and business consulting. The company’s product categories encompass Veeva Development Cloud, Veeva Quality Cloud, Veeva Commercial Cloud, and Veeva Data Cloud.
1. Boston Scientific Corporation (NYSE:BSX)
Boston Scientific Corporation (NYSE:BSX) is one of the most oversold healthcare stocks to invest in. Truist cut the price target on Boston Scientific Corporation (NYSE:BSX) to $90 from $92 on April 15 and maintained a Buy rating on the shares. The rating update came as part of a broader research note previewing fiscal Q1 results in MedTech, with the firm stating that it expects fiscal Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes. It further told investors in a research note that the reduced price target reflects some multiple contraction for the group since the firm’s last valuation update. However, Truist also believes that the stock’s valuation can at a minimum rebound back up to its one-year forward earnings of 23-times.
Boston Scientific Corporation (NYSE:BSX) also received a rating update from RBC Capital on April 14. The firm cut the price target on the stock to $105 from $115 and maintained an Outperform rating on the shares. The rating update came as part of a broader research note previewing Q1 results for MedTech names.
Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments. The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.
While we acknowledge the potential of BSX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BSX and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
